Erratum: Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial (The Lancet (2016) 387(10016) (349–356) (S0140673615005152) (10.1016/S0140-6736(15)00515-2));Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): A randomised clinical trial

The Lancet

Volumn 387, Issue 10016, 2016, Pages 349-356

  Lincoff, A Michael ^a   Mehran, Roxana ^b   Povsic, Thomas J ^c   Zelenkofske, Steven L ^d   Huang, Zhen ^c   Armstrong, Paul W ^e   Steg, P Gabriel ^f   Bode, Christoph ^g   Cohen, Mauricio G ^h   Buller, Christopher ⁱ   Laanmets, Peep ^j   Valgimigli, Marco ^k   Marandi, Toomas ^j   Fridrich, Viliam ^l   Cantor, Warren J ^m   Merkely, Bela ⁿ   Lopez Sendon, Jose ^o   Cornel, Jan H ^p   Kasprzak, Jaroslaw D ^q   Aschermann, Michael ^r   Guetta, Victor ^s   Morais, Joao ^t   Sinnaeve, Peter R ^u   Huber, Kurt ^v   Stables, Rod ^w   Sellers, Mary Ann ^c   Borgman, Marilyn ^a   Glenn, Lauren ^d   Levinson, Arnold I ^x   Lopes, Renato D ^c   Hasselblad, Vic ^c   Becker, Richard C ^y   Alexander, John H ^c   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d Regado Biosciences   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j North Estonia Medical Centre   (Estonia)

^k UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^l NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

^m SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

ⁿ SEMMELWEIS UNIVERSITY   (Hungary)

^o HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^p Medical Centre Alkmaar   (Netherlands)

^q Medical University of Lodz Bieganski Hospital   (Poland)

^r CHARLES UNIVERSITY   (Czech Republic)

^s TEL AVIV UNIVERSITY   (Israel)

^t Cardiology Division   (Portugal)

^u UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^v WILHELMINEN HOSPITAL   (Austria)

^w LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^x UNIVERSITY OF PENNSYLVANIA   (United States)

^y UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANIVAMERSEN; BLOOD CLOTTING FACTOR 9A; HIRULOG; PEGNIVACOGIN; ANTICOAGULANT AGENT; APTAMER; COAGULATING AGENT; HIRUDIN DERIVATIVE; OLIGONUCLEOTIDE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CARDIAC PATIENT; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG HYPERSENSITIVITY; EUROPE; FEMALE; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NORTH AMERICA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; EARLY TERMINATION OF CLINICAL TRIAL; HEMORRHAGE;

AGED; ANTICOAGULANTS; APTAMERS, NUCLEOTIDE; COAGULANTS; DRUG HYPERSENSITIVITY; EARLY TERMINATION OF CLINICAL TRIALS; EUROPE; FACTOR IXA; FEMALE; HEMORRHAGE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; OLIGONUCLEOTIDES; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; RECOMBINANT PROTEINS;

EID: 84959556076     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00678-4     Document Type: Erratum

References (29)

1. DE Winchester, X Wen, WD Brearley, KE Park, RD Anderson, AA Bavry Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the eral of stents and thienopyridines J Am Coll Cardiol 57 2011 1190 1199
2. RP Giugliano, JA White, C Bode et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
3. SV Rao, PR Kaul, L Liao et al. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes Am Heart J 155 2008 369 374
4. R Mehran, S Pocock, E Nikolsky et al. Impact of bleeding on mortality after percutaneous coronary intervention JACC Cardiovasc Interv 4 2011 654 664
5. MA Cavender, MS Sabatine Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials Lancet 384 2014 599 606
6. CP Rusconi, E Scardino, J Layzer et al. RNA aptamers as reversible antagonists of coagulation factor IXa Nature 419 2002 90 94
7. MY Chan, MG Cohen, CK Dyke et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease Circulation 117 2008 2865 2874
8. MY Chan, CP Rusconi, JH Alexander, RM Tonkens, RA Harrington, RC Becker A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor J Thromb Haemost 6 2008 789 796
9. CK Dyke, SR Steinhubl, NS Kleiman et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2006 2490 2497
10. TJ Povsic, WA Wargin, JH Alexander et al. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy Eur Heart J 32 2011 2412 2419
11. TJ Povsic, MG Cohen, R Mehran et al. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR phase IIb trial Am Heart J 161 2011 261 268
12. TJ Povsic, JP Vavalle, LH Aberle et al. A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial Eur Heart J 34 2012 2481 2489
13. R Mehran, SV Rao, DL Bhatt et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
14. K Thygesen, JS Alpert, AS Jaffe, ML Simoons, BR Chaitman, HD White Third universal definition of myocardial infarction Circulation 126 2012 2020 2035
15. P Sundaram, H Kurniawan, ME Byrne, J Wower Therapeutic RNA aptamers in clinical trials Eur J Pharm Sci 48 2013 259 271
16. AD Keefe, S Pai, A Ellington Aptamers as therapeutics Nat Rev Drug Discov 9 2010 537 550
17. SM Nimjee, CP Rusconi, BA Sullenger Aptamers: an emerging class of therapeutics Annu Rev Med 56 2005 555 583
18. EL Howard, KC Becker, CP Rusconi, RC Becker Factor IXa inhibitors as novel anticoagulants Arterioscler Thromb Vasc Biol 27 2007 722 727
19. M Kjalke, D Monroe, M Hoffman et al. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation Thromb Haemost 80 1998 578 584
20. DM Monroe, M Hoffman, HR Roberts Transmission of a procoagulant signal from tissue factor-bearing cells to platelets Blood Coagul Fibrinolysis 7 1996 459 464
21. CR Benedict, J Ryan, B Wolitzky et al. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model J Clin Invest 88 1991 1760 1765
22. GZ Feuertein, A Patel, JR Toomey et al. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats Arterioscler Thromb Vasc Biol 19 1999 2554 2562
23. CJ Refino, S Jeet, L DeGuzman, S Bunting, D Kirchhofer A human antibody that inhibits factor IX/IXa function potently inhibit arterial thrombosis without increasing bleeding Arterioscler Thromb Vasc Biol 22 2002 517 522
24. MG Cohen, DA Purdy, JS Rossi et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention Circulation 122 2010 614 622
25. K-M Song, S Lee, C Ban Aptamers and their biological applications Sensors 12 2012 612 631
26. X Ni, M Castanares, A Mukherjee, SE Lupold Nucleic acid aptamers: clinical applications and promising new horizons Curr Med Chem 18 2011 4206 4214
27. NJ Ganson, SJ Kelly, E Scarlett, JS Sundy, MS Hershfield Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase Arthritis Res Ther 8 2006 R12
28. JS Sundy, NJ Ganson, SJ Kelly et al. Pharmacokinectics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout Arthritis Rheum 56 2007 1021 1028
29. JS Sundy, MS Hershfield Uricase and other novel agents for the management of patients with treatment-failure gout Curr Rheumatol 9 2007 258 264